key: cord-1025233-1jq2iyei
authors: Bennett, T. D.; Moffitt, R. A.; Hajagos, J. G.; Amor, B.; Anand, A.; Bissell, M. M.; Bradwell, K. R.; Bremer, C.; Byrd, J. B.; Denham, A.; DeWitt, P. E.; Gabriel, D.; Garibaldi, B. T.; Girvin, A. T.; Guinney, J.; Hill, E. L.; Hong, S. S.; Jimenez, H.; Kavuluru, R.; Kostka, K.; Lehmann, H. P.; Levitt, E.; Mallipattu, S. K.; Manna, A.; McMurry, J. A.; Morris, M.; Muschelli, J.; Neumann, A. J.; Palchuk, M. B.; Pfaff, E. R.; Qian, J.; Qureshi, N.; Russell, S.; Spratt, H.; Walden, A.; Williams, A. E.; Wooldridge, J. T.; Yoo, Y. J.; Zhang, X. T.; Zhu, R. L.; Austin, C. P.; Saltz, J. H.; Gersing, K.
title: The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction
date: 2021-01-13
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.01.12.21249511
sha: 0686aeecfed70081ad9a327546e425c1ac1cf708
doc_id: 1025233
cord_uid: 1jq2iyei

Background: The majority of U.S. reports of COVID-19 clinical characteristics, disease course, and treatments are from single health systems or focused on one domain. Here we report the creation of the National COVID Cohort Collaborative (N3C), a centralized, harmonized, high-granularity electronic health record repository that is the largest, most representative U.S. cohort of COVID-19 cases and controls to date. This multi-center dataset supports robust evidence-based development of predictive and diagnostic tools and informs critical care and policy. Methods and Findings: In a retrospective cohort study of 1,926,526 patients from 34 medical centers nationwide, we stratified patients using a World Health Organization COVID-19 severity scale and demographics; we then evaluated differences between groups over time using multivariable logistic regression. We established vital signs and laboratory values among COVID-19 patients with different severities, providing the foundation for predictive analytics. The cohort included 174,568 adults with severe acute respiratory syndrome associated with SARS-CoV-2 (PCR >99% or antigen <1%) as well as 1,133,848 adult patients that served as lab-negative controls. Among 32,472 hospitalized patients, mortality was 11.6% overall and decreased from 16.4% in March/April 2020 to 8.6% in September/October 2020 (p = 0.002 monthly trend). In a multivariable logistic regression model, age, male sex, liver disease, dementia, African-American and Asian race, and obesity were independently associated with higher clinical severity. To demonstrate the utility of the N3C cohort for analytics, we used machine learning to predict clinical severity and risk factors over time. Using 64 inputs available on the first hospital day, we predicted a severe clinical course (death, discharge to hospice, invasive ventilation, or extracorporeal membrane oxygenation) using random forest and XGBoost models (AUROC 0.86 and 0.87 respectively) that were stable over time. The most powerful predictors in these models are patient age and widely available vital sign and laboratory values. The established expected trajectories for many vital signs and laboratory values among patients with different clinical severities validates observations from smaller studies, and provides comprehensive insight into COVID-19 characterization in U.S. patients. Conclusions: This is the first description of an ongoing longitudinal observational study of patients seen in diverse clinical settings and geographical regions and is the largest COVID-19 cohort in the United States. Such data are the foundation for machine learning (ML) models that can be the basis for generalizable clinical decision support tools. The N3C Data Enclave is unique in providing transparent, reproducible, easily shared, versioned, and fully auditable data and analytic provenance for national-scale patient-level EHR data. The N3C is built for intensive ML analyses by academic, industry, and citizen scientists internationally. Many observational correlations can inform trial designs and care guidelines for this new disease.

Collaborative (N3C), a centralized, harmonized, high-granularity electronic health record repository that is the 32 largest, most representative U.S. cohort of COVID-19 cases and controls to date. This multi-center dataset supports 33 robust evidence-based development of predictive and diagnostic tools and informs critical care and policy. Methods

and Findings: In a retrospective cohort study of 1,926,526 patients from 34 medical centers nationwide, we 35 stratified patients using a World Health Organization COVID-19 severity scale and demographics; we then 36 evaluated differences between groups over time using multivariable logistic regression. We established vital signs 37 and laboratory values among COVID-19 patients with different severities, providing the foundation for predictive 38 analytics. The cohort included 174,568 adults with severe acute respiratory syndrome associated with SARS-CoV-2 39 (PCR >99% or antigen <1%) as well as 1,133,848 adult patients that served as lab-negative controls. Among 32,472 40 hospitalized patients, mortality was 11.6% overall and decreased from 16.4% in March/April 2020 to 8.6% in 41 September/October 2020 (p = 0.002 monthly trend). In a multivariable logistic regression model, age, male sex, 42 liver disease, dementia, African-American and Asian race, and obesity were independently associated with higher 43 clinical severity. To demonstrate the utility of the N3C cohort for analytics, we used machine learning (ML) to 44 predict clinical severity and risk factors over time. Using 64 inputs available on the first hospital day, we predicted a 45 severe clinical course (death, discharge to hospice, invasive ventilation, or extracorporeal membrane oxygenation) 46 using random forest and XGBoost models (AUROC 0.86 and 0.87 respectively) that were stable over time. The 47 most powerful predictors in these models are patient age and widely available vital sign and laboratory values. The CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021.

As of mid-December 2020, severe acute respiratory syndrome associated with coronavirus-2 (SARS-CoV-2) has 60 infected more than 70 million people and caused more than 1.6 million deaths worldwide [ is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint 3 Because of the broad inclusion criteria, N3C includes cases and appropriate controls for varied analyses including 87 both outpatients and inpatients (Supplemental Table 1 ). N3C includes patients with any encounter after 1/1/2020 88 with 1) one of a set of a priori-defined SARS-CoV-2 laboratory tests or 2) a "strong positive" diagnostic code or 3) 89 two "weak positive" diagnostic codes during the same encounter or on the same date prior to 5/1/2020. The cohort 90 definition is publicly available on GitHub. [c] For N3C patients, encounters in the same health system beginning on or 91 after 1/1/2018 are also included to provide information about pre-existing health conditions ("lookback data"). See

Supplemental Methods for information about N3C architecture, data ingestion, and integration.

We conducted a retrospective cohort study of adults CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. 

We developed models to predict patient-specific maximum clinical severity: hospitalization with death, discharge to 138 hospice, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) versus hospitalization 139 without any of those. To avoid immortal time bias, we only included patients with at least one hospital overnight.

We split the hospitalized laboratory-confirmed positive cohort into randomly selected 70% training and 30% testing 141 cohorts stratified by outcome proportions and held out the testing set. We chose a broad set of potential predictors 142 present for at least 15% of the training set (Supplemental Table 2 ). The input variables are the most abnormal value 143 on the first calendar day of the hospital encounter. When patients did not have a laboratory test value on the first 144 calendar day, we imputed normal values for specialized labs (e.g. ferritin, procalcitonin) and the median cohort 145 value for common labs (e.g. sodium, albumin) (Supplemental Table 2 ). We compared several analytical approaches 146 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint 6 with varying flexibility and interpretability: logistic regression +/-L1 and L2 penalty, random forest, support vector 147 machines, and XGBoost (github.com/dmlc/xgboost).

We internally validated models and limited overfitting using 5-fold cross-validation and evaluated models using the 

As of December 7, 2020, data from 34 sites was harmonized and integrated into the N3C release set. The cohort 167 includes data about 1,926,526 patients (Supplemental Table 1 Table 1 ) indicate a diverse patient cohort that is 170 representative of many segments of the U.S. population. Importantly, African-American and Hispanic patients, who 171 have suffered disproportionately from COVID-19 6 , are represented in sufficient numbers to support robust subgroup 172 analyses, pathophysiologic hypothesis generation, and testing of algorithms and models to avoid bias (Table 1) .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. 

Of those with a positive test, 32,472 (18.6%) were hospitalized. The median length of hospital stay was 5 days (IQR 199 2 to 10). Mortality (including discharge to hospice) was 11.6% among hospitalized patients (Table 1) 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint 11 shown over each severity group bar. Figure 2b shows how the age distribution of hospitalized patients has changed 214 during 2020. The percentage of patients from each month is shown over each age bracket bar. Older patients (darker 215 blue) were more prominent in the spring and the fall, with more younger patients (lighter blue/teal) in the summer. 216 Figure 2c shows the evolution of antimicrobial and immunomodulatory treatment regimens for hospitalized patients 217 (top 3 severity strata, see Table 1) Figure 1c ). Mean body mass index (BMI) was 30 or above for all severity groups (Table   225 1). In a multivariable logistic regression model, age, male sex, liver disease, dementia, African-American and Asian 226 race, and obesity (BMI > 30) were independently associated with higher patient-specific maximum clinical severity 227 (invasive ventilation, ECMO, death, or discharge to hospice versus none of those, Supplemental Table 4 ). As a hospital encounter progressed, those who ultimately developed higher clinical severity (invasive ventilation, 234 ECMO, or death) tended to have progressively more abnormal (higher) mean heart rate (HR), respiratory rate (RR), 235 and temperature than those who did not (Figure 3a) . Mean diastolic blood pressure (DBP) and oxygen saturation 236 (SpO 2 ) among those who ultimately died continued to become more abnormal (lower) while those who were 237 invasively ventilated or on ECMO became more normal (higher, Figure 3a CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint 12 those who did not (Figures 3a and 3b) . These findings support the hypothesis that clinical severity can be predicted 242 using information available early in a hospital course (see prediction models). Table 1 ). Figure 3b shows the median (line) and interquartile range (bars) of each laboratory test on 251 each hospital day, stratified by the same severity groups. BNP = brain natriuretic peptide. Table 5a ). More patients received hydrocortisone, 272 methylprednisolone, and prednisone than dexamethasone (Supplemental Table 5a ). The trial indicating survival 273 benefit from dexamethasone was published in July 2020. 9 Other steroids also have modestly supportive clinical trial 274 data. 10 275 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. 

We developed several models that accurately predict a severe clinical course using data from the first hospital 282 calendar day (Supplemental Figure 6 and Supplemental Table 6 ). The models with the best discrimination of severe 283 versus non-severe clinical course were built using XGBoost (AUROC 0.87) and random forest (AUROC 0.86). Both 284 are flexible nonlinear tree-based models that provide interpretability with a variable importance metric (Figure 4 ).

Importantly, discrimination by the two models was stable over time (March-May 2020 and June-October 2020, 286 Supplemental Table 6 ). This indicates that the models did not train on health care processes only typical during the 287 pandemic's chaotic first wave. Commonly collected variables (age, SpO 2 , RR, blood urea nitrogen, systolic blood 288 pressure, and aspartate aminotransferase) were among the inputs with the highest variable importance for both 289 models (Figure 4 ). Site heterogeneity in the distribution of predictors of severe COVID-19 disease including age, race, ethnicity, and 317 existing comorbidities (e.g. diabetes) has complicated interpretation of their independent impact on outcomes. Like 318 others, we found that age, male sex 1 , African-American race 6,11 and obesity 12,13 were associated with greater clinical 319 severity. Associations of liver disease and dementia with COVID-19 severity have also been reported 14,15 . We found 320 that patients with rheumatologic disease had lower clinical severity. This is consistent with reports that after 321 adjustment for age, diabetes, and renal impairment, patients with rheumatologic disease on some treatment regimens 322 have lower risk of hospitalization 16 . Increased risk of intubation and death has been inconsistently found among 323 patients with blood types AB, A, and B relative to type O. [17] [18] [19] In contrast, we found that blood type AB was 324 protective. 325 326 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint

We also found significant treatment regimen heterogeneity for inpatients with COVID-19. Some medications have 327 fallen out of favor (e.g. hydroxychloroquine, azithromycin); others are the subject of ongoing studies (e.g. anakinra, 328 tocilizumab). For most treatments, the balance of risks and benefits has not been evaluated rigorously in randomized 329 controlled trials. Ongoing monitoring for adverse effects in observational data like N3C will be important. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 13, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint 517 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint

Association between statin use and outcomes in patients with coronavirus 495 disease 2019 (COVID-19): a nationwide cohort study

The National COVID Cohort Collaborative (N3C): Rationale, Design

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal 500 common outcome measure set for COVID-19 clinical research

Improving Survival of Critical Care Patients With 502

Coronavirus Disease 2019 in England: A National Cohort Study

Disparities In Outcomes Among COVID-19 Patients In A Large 505

Health Care System In California

Trends in COVID-19 Risk-Adjusted Mortality Rates

COVID-19 and the cardiovascular system: implications for risk 509 assessment, diagnosis, and treatment options

Dexamethasone in Hospitalized Patients with 511

Effect of Hydrocortisone on Mortality and Organ Support in Patients 513 With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Hospitalization and Mortality among Black Patients and 516

White Patients with Covid-19

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results 518 From an Integrated Health Care Organization

Obesity as a risk factor for COVID-19 mortality in women and men 520 in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease

The Impact of Dementia on the Clinical Outcome of COVID-523 19: A Systematic Review and Meta-Analysis

High mortality rates for SARS-CoV-2 infection in patients with pre-525 existing chronic liver disease and cirrhosis: Preliminary results from an international registry

Rheumatic disease and COVID-19: epidemiology and outcomes

Blood type and outcomes in patients with COVID-19

Associations between blood type and COVID-19 infection, intubation, and 532 death

Association Between ABO and Rh Blood Groups and SARS-534

CoV-2 Infection or Severe COVID-19 Illness : A Population-Based Cohort Study

Clinical Characteristics of Covid-19 in New York City

the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Presenting Characteristics, Comorbidities, and Outcomes 542

Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

ICU and Ventilator Mortality Among Critically Ill Adults With 544

International electronic health record-derived COVID-19 clinical 546 course profiles: the 4CE consortium

Clinical Mortality in a Large COVID-19 Cohort: Observational Study

Risk factors for developing into critical COVID-19 patients in Wuhan, China: A 550 multicenter, retrospective, cohort study

Clinical determinants for fatality of 44,672 patients with COVID-19

Retraction-Hydroxychloroquine or chloroquine with or without a 556 macrolide for treatment of COVID-19: a multinational registry analysis

Cardiovascular Disease, Drug Therapy, and Mortality in 558

e102. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C 369 Data Enclave covid.cd2h.org/enclave and supported by NCATS U24 TR002306 to Drs. Haendel CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. Conduct. Investigators wishing to access the limited dataset must also supply an institutional IRB protocol. All 466 requests for data access are reviewed by the NIH Data Access Committee. A full description of the N3C Enclave 467 governance has been published; 3 information about how to apply for access is available on the NCATS website: 468 https://ncats.nih.gov/n3c/about/applying-for-access. Reviewers and health authorities will be given access 469 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 13, 2021. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted January 13, 2021. ; https://doi.org/10.1101/2021.01.12.21249511 doi: medRxiv preprint